ERBB2 and gastrointestinal stromal tumor: This approach has been therapeutically beneficial for several cancer types with particular genomic alterations, including BCR-ABL kinase inhibition for chronic myeloid leukemia and KIT inhibition for gastrointestinal stromal tumor (GIST), as well as BRAF and Her2 inhibition for multiple tumor types1,2.